Intercept Pharmaceuticals, Inc. (ICPT)
Nov 8, 2023 - ICPT was delisted (reason: acquired by Alfasigma)
19.00
0.00 (0.00%)
Last trade price
Intercept Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ICPT stock had an average target of 22.5, with a low estimate of 14 and a high estimate of 54.
Analyst Consensus: Hold
* Price targets were last updated on Sep 27, 2023.
Analyst Ratings
The average analyst rating for ICPT stock from 10 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '23 | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 4 | 4 | 7 | 7 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $15 → $19 | Strong Buy → Hold | Downgrades | $15 → $19 | n/a | Sep 27, 2023 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $19 | Hold | Maintains | $12 → $19 | n/a | Sep 27, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $19 | Strong Buy → Hold | Downgrades | $19 | n/a | Sep 27, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $20 → $19 | Strong Buy → Hold | Downgrades | $20 → $19 | n/a | Sep 27, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | n/a | Aug 3, 2023 |
Financial Forecast
Revenue This Year
337.77M
from 285.71M
Increased by 18.22%
Revenue Next Year
368.48M
from 337.77M
Increased by 9.09%
EPS This Year
-1.33
from 6.56
EPS Next Year
2.09
from -1.33
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 354.5M | 457.8M | 542.4M | 518.4M | 555.4M |
| Avg | 337.8M | 368.5M | 368.7M | 370.6M | 354.6M |
| Low | 318.5M | 304.3M | 258.4M | 228.6M | 190.6M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 24.1% | 35.5% | 47.2% | 40.6% | 49.8% |
| Avg | 18.2% | 9.1% | 0.1% | 0.5% | -4.3% |
| Low | 11.5% | -9.9% | -29.9% | -38.0% | -48.6% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -0.56 | 3.02 | 2.90 | 3.40 | 3.92 |
| Avg | -1.33 | 2.09 | 1.77 | 1.70 | 1.65 |
| Low | -3.22 | 0.74 | 0.16 | 0.55 | -0.09 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | 38.9% | 92.5% | 130.4% |
| Avg | - | - | -15.3% | -3.8% | -3.2% |
| Low | - | - | -92.5% | -68.9% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.